Zacks Small Cap Has Optimistic Outlook of EVAX Q1 Earnings

Evaxion Biotech A/S (NASDAQ:EVAX) – Equities research analysts at Zacks Small Cap lifted their Q1 2025 earnings per share estimates for Evaxion Biotech A/S in a research note issued to investors on Thursday, February 6th. Zacks Small Cap analyst B. Sorensen now forecasts that the company will post earnings of ($0.65) per share for the quarter, up from their previous estimate of ($0.75). The consensus estimate for Evaxion Biotech A/S’s current full-year earnings is ($0.15) per share. Zacks Small Cap also issued estimates for Evaxion Biotech A/S’s Q2 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.12) EPS and FY2025 earnings at ($1.32) EPS.

EVAX has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 target price on shares of Evaxion Biotech A/S in a research report on Monday, February 3rd. Lake Street Capital lowered their price objective on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, February 4th.

Evaxion Biotech A/S Stock Performance

Shares of EVAX stock opened at $2.62 on Monday. The company has a quick ratio of 2.80, a current ratio of 1.00 and a debt-to-equity ratio of 7.99. The stock has a fifty day moving average of $4.37 and a 200 day moving average of $10.26. The firm has a market capitalization of $3.07 million, a price-to-earnings ratio of -1.81 and a beta of -0.28. Evaxion Biotech A/S has a 52 week low of $2.22 and a 52 week high of $23.70.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Catalina Capital Group LLC bought a new stake in shares of Evaxion Biotech A/S (NASDAQ:EVAX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned approximately 2.98% of Evaxion Biotech A/S as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 11.04% of the company’s stock.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.